Loading stock data…
Compugen Ltd. (CGEN)
$2.56-0.03 (-1.16%)
Market ClosedLast close Sep 8
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Compugen Ltd. in the Healthcare sector is trading at $2.56 with a market capitalization of $245M. Wall Street consensus targets $4.60 (5 analysts), implying a +79.7% move over the next 12 months. The stock is currently 21% below its 52-week high of $3.24, remaining 17.4% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +79.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $2.60M↑ | $2.18M↓ | $67.33M↑ | $1.89M↑ | $1.26M |
| Gross Profit | -$92,000↓ | $352,000↓ | $63.80M↑ | $241,000↑ | -$408,000 |
| Operating Income | -$8.84M↑ | -$9.02M↓ | $56.04M↑ | -$7.89M↑ | -$8.43M |
| Net Income | -$7.01M↑ | -$7.67M↓ | $56.84M↑ | -$6.98M↑ | -$7.34M |
Peer Comparison
JNJUNHPFE
Fundamentals
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consist...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$245.34M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
6.82
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.79
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
39.66%
Volume
Today's trading volume
192,800
Recent News
All You Need to Know About Compugen (CGEN) Rating Upgrade to Buy
Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Are Medical Stocks Lagging Compugen (CGEN) This Year?
Here is how Compugen (CGEN) and Envoy Medical, Inc. (COCH) have performed compared to their sector so far this year.
Compugen Ltd (CGEN) (Q2 2026) Earnings Call Highlights: Advancing COM701 with Strong Cash ...
Compugen Ltd (CGEN) reports solid cash position and progress in its MyOvarian trial, despite revised placebo assumptions and a distant timeline for key partnership milestones.
Compugen Ltd. Q2 2026 Earnings Call Summary
Moby summary of Compugen Ltd.'s Q2 2026 earnings call
Compugen Q2 Earnings Call Highlights
Compugen (NASDAQ:CGEN) said its second-quarter 2026 progress included continued enrollment in its MAIA-ovarian study of COM701, advancing partner-led programs with AstraZeneca and Gilead, and a cash runway projected to extend into 2029. President and Chief Executive Officer Eran Ophir described the